Durability of immune responses to the BNT162b2 mRNA vaccine
Preprint
- 30 September 2021
- preprint
- Published by Cold Spring Harbor Laboratory
Abstract
The development of the highly efficacious mRNA vaccines in less than a year since the emergence of SARS-CoV-2 represents a landmark in vaccinology. However, reports of waning vaccine efficacy, coupled with the emergence of variants of concern that are resistant to antibody neutralization, have raised concerns about the potential lack of durability of immunity to vaccination. We recently reported findings from a comprehensive analysis of innate and adaptive immune responses in 56 healthy volunteers who received two doses of the BNT162b2 vaccination. Here, we analyzed antibody responses to the homologous Wu strain as well as several variants of concern, including the emerging Mu (B.1.621) variant, and T cell responses in a subset of these volunteers at six months (day 210 post-primary vaccination) after the second dose. Our data demonstrate a substantial waning of antibody responses and T cell immunity to SARS-CoV-2 and its variants, at 6 months following the second immunization with the BNT162b2 vaccine. Notably, a significant proportion of vaccinees have neutralizing titers below the detection limit, and suggest a 3rd booster immunization might be warranted to enhance the antibody titers and T cell responses.Keywords
This publication has 17 references indexed in Scilit:
- Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman PrimatesPublished by Cold Spring Harbor Laboratory ,2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Durability of Responses after SARS-CoV-2 mRNA-1273 VaccinationThe New England Journal of Medicine, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineThe New England Journal of Medicine, 2020
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsThe New England Journal of Medicine, 2020
- Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS‐CoV‐2 Neutralizing AntibodiesCurrent Protocols in Immunology, 2020
- Rapid Generation of Neutralizing Antibody Responses in COVID-19 PatientsCell Reports Medicine, 2020
- An Infectious cDNA Clone of SARS-CoV-2Cell Host & Microbe, 2020
- Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virusPLoS Neglected Tropical Diseases, 2018
- Heterogeneity and longevity of antibody memory to viruses and vaccinesPLoS Biology, 2018